Complex psychotropic polypharmacy in bipolar disorder across varying mood polarities: A prospective cohort study of 2712 inpatients

Journal of Affective Disorders

Volumn 221, Issue , 2017, Pages 6-10

  Golden, Julia C ^a   Goethe, John W ^a,b   Woolley, Stephen B ^a  

^a INSTITUTE OF LIVING   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Bipolar disorder; Pharmacotherapy; Polypharmacy; Rehospitalization

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE; CARBAMAZEPINE; DULOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; NEFAZODONE; OXCARBAZEPINE; PSYCHOTROPIC AGENT; TOPIRAMATE; TRAZODONE; VALPROATE SEMISODIUM; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BORDERLINE STATE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITAL READMISSION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; AFFECT; DRUG EFFECTS; HOSPITAL PATIENT; MIDDLE AGED; PSYCHOLOGY; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AFFECT; BIPOLAR DISORDER; FEMALE; HUMANS; INPATIENTS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYPHARMACY; PROSPECTIVE STUDIES; PSYCHOTROPIC DRUGS; YOUNG ADULT;

EID: 85020891588     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2017.06.005     Document Type: Article

References (34)

1. Alda, M., Yatham, L.N., Is monotherapy as good as polypharmacy in long-term treatment of bipolar disorder?. Can. J. Psychiatry 54 (2009), 719–725.
2. Baek, J.H., Ha, K., Yatham, L.N., Chang, J.S., Ha, T.H., Jeon, H.J., Hong, K.S., Chang, S.M., Ahn, Y.M., Cho, H.S., Moon, E., Cha, B., Choi, J.E., Joo, Y.H., Joo, E.J., Lee, S.Y., Park, Y., Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines. J. Clin. Psychopharmacol. 34 (2014), 577–587.
3. Baldessarini, R.J., Perry, R., Pike, J., Factors associated with treatment nonadherence among US bipolar disorder patients. Hum. Psychopharmacol. 23 (2008), 95–105.
4. Bauer, M., Glenn, T., Alda, M., Sagduyu, K., Marsh, W., Grof, P., Munoz, R., Baethge, C., Lewitzka, U., Pilhatsch, M., Bauer, R., Whybrow, P.C., Regularity in daily mood stabilizer dosage taken by patients with bipolar disorder. Pharmacopsychiatry 46 (2013), 163–168.
5. Bauer, R., Glenn, T., Alda, M., Sagduyu, K., Marsh, W., Grof, P., Munoz, R., Murray, G., Ritter, P., Lewitzka, U., Severus, E., Whybrow, P.C., Bauer, M., Antidepressant dosage taken by patients with bipolar disorder: factors associated with irregularity. Int. J. Bipolar Disord., 1, 2013, 26.
6. Bridler, R., Haberle, A., Muller, S.T., Cattapan, K., Grohmann, R., Toto, S., Kasper, S., Greil, W., Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur. Neuropsychopharmacol. 25 (2015), 763–772.
7. Curran, G., Ravindran, A., Lithium for bipolar disorder: a review of the recent literature. Expert Rev. Neurother. 14 (2014), 1079–1098.
8. El-Mallakh, R.S., Vohringer, P.A., Ostacher, M.M., Baldassano, C.F., Holtzman, N.S., Whitham, E.A., Thommi, S.B., Goodwin, F.K., Ghaemi, S.N., Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. J. Affect. Disord. 184 (2015), 318–321.
9. Fornaro, M., De Berardis, D., Koshy, A.S., Perna, G., Valchera, A., Vancampfort, D., Stubbs, B., Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr. Dis. Treat. 12 (2016), 719–735.
10. Frye, M.A., Ketter, T.A., Leverich, G.S., Huggins, T., Lantz, C., Denicoff, K.D., Post, R.M., The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J. Clin. Psychiatry 61 (2000), 9–15.
11. Goldberg, J.F., Brooks, J.O. 3rd, Kurita, K., Hoblyn, J.C., Ghaemi, S.N., Perlis, R.H., Miklowitz, D.J., Ketter, T.A., Sachs, G.S., Thase, M.E., Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J. Clin. Psychiatry 70 (2009), 155–162.
12. Goodwin, G.M., Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 23 (2009), 346–388.
13. Gören, J.L., Tewksbury, A., Drug Interactions and Polypharmacy. Ritsner, M.S., (eds.) Polypharmacy in Psychiatry Practice, 2013, Springer, Dordrecht, Netherlands, 45–74.
14. Greil, W., Haberle, A., Haueis, P., Grohmann, R., Russmann, S., Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J. Affect. Disord. 136 (2012), 534–542.
15. Grunze, H., The role of polypharmacy in bipolar disorder treatment guidelines. Ritsner, M.S., (eds.) Polypharmacy in Psychiatry Practice, 2013, Springer, Dordrecht, Netherlands, 275–297.
16. Grunze, H., Vieta, E., Goodwin, G.M., Bowden, C., Licht, R.W., Moller, H.J., Kasper, S., The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J. Biol. Psychiatry 10 (2009), 85–116.
17. Hayes, J.F., Marston, L., Walters, K., Geddes, J.R., King, M., Osborn, D.P., Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry 15 (2016), 53–58.
18. Keck, P.E., Orsulak, P.J., Cutler, A.J., Sanchez, R., Torbeyns, A., Marcus, R.N., McQuade, R.D., Carson, W.H., Group, C.N.S., Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J. Affect. Disord. 112 (2009), 36–49.
19. Kushner, S.F., Khan, A., Lane, R., Olson, W.H., Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 8 (2006), 15–27.
20. Levine, J., Chengappa, K.N., Brar, J.S., Gershon, S., Yablonsky, E., Stapf, D., Kupfer, D.J., Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord. 2 (2000), 120–130.
21. Miller, S., Dell'Osso, B., Ketter, T.A., The prevalence and burden of bipolar depression. J. Affect. Disord. 169:Suppl 1 (2014), S3–S11.
22. Misawa, F., Shimizu, K., Fujii, Y., Miyata, R., Koshiishi, F., Kobayashi, M., Shida, H., Oguchi, Y., Okumura, Y., Ito, H., Kayama, M., Kashima, H., Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry, 11, 2011, 118.
23. Mojtabai, R., Olfson, M., National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch. Gen. Psychiatry 67 (2010), 26–36.
24. Mukattash, T.L., Alzoubi, K.H., Abu El-Rub, E., Jarab, A.S., Al-Azzam, S.I., Khdour, M., Shara, M., Al Hamarneh, Y.N., Prevalence of non-adherence among psychiatric patients in Jordan, a cross sectional study. Int. J. Pharm. Pract. 24 (2016), 217–221.
25. Pacchiarotti, I., Valenti, M., Colom, F., Rosa, A.R., Nivoli, A.M., Murru, A., Sanchez-Moreno, J., Vieta, E., Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J. Affect. Disord. 129 (2011), 321–326.
26. Sachs, G.S., Peters, A.T., Sylvia, L., Grunze, H., Polypharmacy and bipolar disorder: what's personality got to do with it?. Int. J. Neuropsychopharmacol. 17 (2014), 1053–1061.
27. SPSS, Statistical Package for the Social Sciences, 19.0 ed. 2010, IBM Corp., Armonk, NY.
28. Suppes, T., Dennehy, E.B., Hirschfeld, R.M., Altshuler, L.L., Bowden, C.L., Calabrese, J.R., Crismon, M.L., Ketter, T.A., Sachs, G.S., Swann, A.C., Texas Consensus Conference Panel on Medication Treatment of Bipolar, D., The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66 (2005), 870–886.
29. Truman, C.J., Goldberg, J.F., Ghaemi, S.N., Baldassano, C.F., Wisniewski, S.R., Dennehy, E.B., Thase, M.E., Sachs, G.S., Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J. Clin. Psychiatry 68 (2007), 1472–1479.
30. Walpoth-Niederwanger, M., Kemmler, G., Grunze, H., Weiss, U., Hortnagl, C., Strauss, R., Blasko, I., Hausmann, A., Treatment patterns in inpatients with bipolar disorder at a psychiatric university hospital over a 9-year period: focus on mood stabilizers. Int. Clin. Psychopharmacol. 27 (2012), 256–266.
31. Weinstock, L.M., Gaudiano, B.A., Epstein-Lubow, G., Tezanos, K., Celis-Dehoyos, C.E., Miller, I.W., Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission. Psychiatry Res. 216 (2014), 24–30.
32. Wolfsperger, M., Greil, W., Rossler, W., Grohmann, R., Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J. Affect. Disord. 99 (2007), 9–17.
33. Yatham, L.N., Kennedy, S.H., Parikh, S.V., Schaffer, A., Beaulieu, S., Alda, M., O'Donovan, C., Macqueen, G., McIntyre, R.S., Sharma, V., Ravindran, A., Young, L.T., Milev, R., Bond, D.J., Frey, B.N., Goldstein, B.I., Lafer, B., Birmaher, B., Ha, K., Nolen, W.A., Berk, M., Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 15 (2013), 1–44.
34. Yerevanian, B.I., Koek, R.J., Mintz, J., Akiskal, H.S., Bipolar pharmacotherapy and suicidal behavior Part 2. The impact of antidepressants. J. Affect. Disord. 103 (2007), 13–21.